Addex Therapeutics Ltd.

Listed Company

ADXNCIK 0001574232NasdaqNon-AcceleratedPharmaceutical PreparationsV8CHFY ends Dec 31

Period

FY 2024

Revenue

—

Net Income

$7.06M

Total Assets

—

Equity

—

Shares Out

147.83M

Op. Cash Flow

—

Business

Addex Therapeutics Ltd. is a clinical-stage pharmaceutical company focused on developing orally available small molecule allosteric modulators for neurological and respiratory conditions. Its main products and drug candidates include dipraglurant (an mGlu5 NAM), ADX71149 (an mGlu2 PAM) and a portfolio of GABAB PAM candidates for substance use disorder and chronic cough. The company organizes its activities into internally developed programs, partnered programs and a minority equity interest in the Neurosterix spin-out. It pursues worldwide development through collaborations, licensing, third‑party manufacturing and international clinical trial sites.

Summary from filing dated 2025-05-15

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	Dec 31, 2025 2025-12-31	Dec 31, 2024 2024-12-31	Dec 31, 2023 2023-12-31
Consolidated Statements of Profit or Loss	—	—	—
Revenue from contract with customer	29,972	404,102	2
Other income	142,888	5,940	4,235
Operating costs	—	—	—
Research and development	671,651	854,305	1
General and administration	2	2	3
Total operating costs	3	3	4
Operating loss	−3	−3	−2
Interest Income	—	26,595	63,964
Finance expense	15,547	3,547	321,150
Finance result	−15,547	23,048	−257,186
Share of net loss of investments accounted for using the equity method	−4	−2	—
Net loss before tax from continuing operations	−7	−5	−3
Income tax expense	0	0	0
Net loss from continuing operations	−7	−5	−3
Net profit / (loss) from discontinued operations (attributable to equity holders of the Group)	114,342	12	−8
Net profit / (loss) for the period	−7	7	−11
Basic profit / (loss) per share for profit/(loss) attributable to the ordinary equity holders of the Company	−0.06	0.07	−0.14
From continuing operations	−0.06	−0.05	−0.03
From discontinued operations	—	0.12	−0.11
Diluted profit / (loss) per share for profit/ (loss) attributable to the ordinary equity holders of the Company	−0.06	0.07	−0.14
From continuing operations	−0.06	−0.05	−0.03
From discontinued operations	—	0.12	−0.11

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	Dec 31, 2025 2025-12-31	Dec 31, 2024 2024-12-31
Consolidated Balance Sheets	—	—
ASSETS	—	—
Current assets	—	—
Cash and cash equivalents	2	3
Other financial assets	5,130	6,496
Trade and other receivables	20,087	15,513
Prepayments	16,295	169,649
Other short-term assets	—	7,967
Total current assets	2	4
Non-current assets	—	—
Right-of-use assets	33,530	41,578
Intangible assets	0	0
Equipment	707	1,131
Non-current financial assets	7,086	7,089
Investment accounted for using the equity method	4	7
Financial assets at fair value through other comprehensive income	285,962	—
Derivative financial instrument	509,067	—
Total non-current assets	5	7
Total assets	6	11
LIABILITIES AND EQUITY	—	—
Current liabilities	—	—
Current lease liabilities	7,680	7,306
Payables and accruals	1	794,787
Total current liabilities	1	802,093
Non-current liabilities	—	—
Non-current lease liabilities	27,008	34,688
Retirement benefits obligations	371,608	164,251
Total non-current liabilities	398,616	198,939
Equity	—	—
Share capital	2	2
Share premium	267	266
Other equity	65	65
Treasury shares reserve	1	869,708
Other reserves	32	31
Accumulated deficit	−360	−353
Total equity	5	10
Total liabilities and equity	6	11

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	Dec 31, 2025 2025-12-31	Dec 31, 2024 2024-12-31	Dec 31, 2023 2023-12-31
Consolidated Statements of Cash Flows	—	—	—
Net profit / (loss) for the period	−7	7	−11
Adjustments for:	—	—	—
Net gain on Neurosterix Transaction	114,342	14	—
Fair value of services received at zero cost recorded as income	141,018	—	—
Fair value of services received at zero cost recorded as other operating costs	141,018	—	—
Value of share-based services	70,820	502,964	2
Post-employment benefits	−7,218	−95,219	−62,643
Share of the net loss of associates	−4	−2	—
Depreciation	8,472	260,120	305,952
Net gain related to lease modification	—	2,770	318
Finance cost / (income) net	−37,607	99,628	−312,602
Decrease / (increase) in other financial assets	1,366	−5,648	2,317
Decrease / (increase) in trade and other receivables	−4,574	93,107	306,514
Decrease in contract asset	—	40,907	140,534
Decrease / (increase) in prepayments	153,354	−164,284	53,386
Decrease / (increase) in other current assets	7,967	−7,967	—
Increase / (decrease) in payables and accruals	391,234	−1	−613,205
Decrease in deferred income	—	−38,401	324,210
Net cash used in operating activities	−2	−5	−8
Cash flows from / (used in) investing activities	—	—	—
Consideration from Neurosterix Transaction	114,342	5	—
Legal fees paid for Neurosterix Transaction	—	473,270	—
Investment in Stalicla SA - preferred shares	285,962	—	—
Investment in Stalicla SA - derivative financial instruments	509,067	—	—
Purchase of property, plant and equipment	0	1,273	6,842
Net cash from/(used in) investing activities	−680,687	5	−6,842
Cash flows from financing activities	—	—	—
Sale of treasury shares	1	240,899	2
Cost paid on sale of treasury shares	28,850	25,782	48,051
Cost of treasury share issuance	6,292	—	53,600
Proceeds from the exercise of pre-funded warrants	—	—	3
Costs paid on exercise of pre-funded warrants	—	36,457	163,069
Principal element of lease payment	7,306	73,688	281,793
Interest received	—	9,165	63,964
Interest paid	2,421	9,219	21,607
Net cash from financing activities	1	104,918	5
Decrease in cash and cash equivalents	−2	−623,425	−3
Cash and cash equivalents at end of the year	—	—	—
Exchange difference on cash and cash equivalents	−35,186	99,682	−356,948
Cash and cash equivalents at end of the year	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro